Defining Value: The Need for a Longer, Broader View

Pharmacoeconomics. 2017 Jul;35(7):669-672. doi: 10.1007/s40273-017-0503-7.

Authors

Tomas J Philipson¹, Sachin Kamal-Bahl², Anupam B Jena^{3

4}

Affiliations

¹ Irving B. Harris Graduate School of Public Policy Studies, University of Chicago, 1155 E. 60th Street, Chicago, IL, 60637, USA. t-philipson@uchicago.edu.
² Innovation Center, Global Health and Value, Pfizer Inc., 500 Arcola Road, Collegeville, PA, 19426, USA.
³ Department of Health Care Policy, Harvard Medical School, Boston, MA, USA.
⁴ Massachusetts General Hospital, Boston, MA, USA.

PMID: 28337720
DOI: 10.1007/s40273-017-0503-7

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Cost-Benefit Analysis
Drug Approval
Drug Costs / trends*
Economics, Pharmaceutical*
Humans
United States